Sign up USA
Proactive Investors - Run By Investors For Investors

Namaste Technologies inks deal with BlueSky Biologicals to distribute CBD products in the UK and Europe

Namaste will distribute BlueSky’s range of products, which includes dietary supplements and a pet care line
CBD oil and cannabis leaves
Namaste’s subsidiary Cannmart offers cannabis products through its e-commerce platform

Namaste Technologies Inc (CVE:N, OTCQB:NXTTF) inked a deal with BlueSky Biologicals Inc to distribute its hemp-derived cannabidiol products in the United Kingdom and Europe.

Its subsidiary Namaste Bahamas will distribute BlueSky’s range of products, which includes dietary supplements, personal care, food and beverages and a pet care line.

READ: Namaste Technologies pushes ahead with plan to up-list to Nasdaq

Namaste brings its subsidiaries’ products to the online medical and recreational markets through its subsidiary Cannmart, an e-commerce cannabis platform.

“We have a well-established market in the UK and with recent changes in federal regulations we are now able to launch CBD sales into one of our strongest markets,” said Namaste CEO Sean Dollinger in the company’s press release.

The Vancouver-based company recently signed a wholesale supply agreement with Kief Cannabis Company Ltd, a producer of small-batch, artisan-crafted cannabis.

It has also signed a deal to buy bulk medical cannabis products from Tilray Inc (NASDAQ:TLRY).

Namaste has plans to uplist to the Nasdaq in the hopes of reaching a larger audience of retail and institutional investors.

Shares of Namaste were up more than 2% to US$2.79 in Wednesday afternoon trading.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use